Source comparison
Tesamorelin vs Ipamorelin: Comparative GHRH-R and GHSR-1a Receptor Research
Tesamorelin vs Ipamorelin: Comparative GHRH-R and GHSR-1a Receptor Research In Vitro Research Overview Tesamorelin and ipamorelin represent distinct research compounds studied extensively in cell-based assay formats for their selective receptor interactions wi
This comparison does not assign a generated winner or score.
- Tesamorelin vs Ipamorelin: Comparative GHRH-R and GHSR-1a Receptor Research
- In Vitro Research Overview
- Tesamorelin and ipamorelin represent distinct research compounds studied extensively in cell-based assay formats for their selective receptor interactions within growth hormone regulatory pathways. These compounds demonstrate differential receptor selectivity profiles, with tesamorelin exhibiting high affinity for growth hormone-releasing hormone receptor (GHRH-R) systems and ipamorelin showing preferential binding to growth hormone secretagogue receptor 1a (GHSR-1a). Published in vitro research characterizes their molecular interactions, binding affinity profiles, and downstream pathway engagement in defined cell model systems under controlled laboratory conditions.
- Receptor Pharmacology and Mechanism of Action
- Tesamorelin GHRH-R Interactions
- Tesamorelin functions as a synthetic growth hormone-releasing hormone analog demonstrating selective agonist activity at GHRH-R, a class B G-protein coupled receptor. Competitive radioligand binding assays reveal nanomolar binding affinities for GHRH-R expressed in heterologous cell systems. Functional assays utilizing cAMP accumulation endpoints demonstrate robust Gαs/adenylyl cyclase pathway activation following receptor engagement. Cell-based reporter assays show concentration-dependent increases in intracellular cAMP levels, with EC50 values typically ranging in the low nanomolar range across multiple cell model systems.
- The compound exhibits enhanced proteolytic stability compared to native GHRH peptides, attributed to specific amino acid substitutions that reduce enzymatic degradation while maintaining high receptor binding affinity. Saturation binding experiments using radiolabeled tesamorelin demonstrate reversible, saturable binding kinetics consistent with specific receptor interactions.
- Ipamorelin GHSR-1a Selectivity
- Ipamorelin acts via selective GHSR-1a activation, a class A G-protein coupled receptor linked to Gq/11 signaling cascades. Competitive radioligand binding assays demonstrate high selectivity for GHSR-1a over related peptide receptors, including minimal cross-reactivity with ACTH, cortisol, prolactin, and TSH receptor systems. Functional cell-based assays utilizing calcium mobilization endpoints reveal robust intracellular calcium flux responses following receptor activation.
- The compound demonstrates pentapeptide structure-activity relationships optimized for GHSR-1a selectivity. Displacement binding studies using [125I]-ghrelin show competitive inhibition profiles with Ki values in the nanomolar range. Calcium flux assays in GHSR-1a-expressing cell lines demonstrate concentration-dependent responses with steep Hill coefficients indicative of cooperative binding mechanisms.
- Comparative Binding Affinity Profiles
- Receptor Selectivity Analysis
- Direct comparative binding studies reveal distinct selectivity profiles between tesamorelin and ipamorelin across growth hormone regulatory receptor subtypes. Tesamorelin exhibits >1000-fold selectivity for GHRH-R over GHSR-1a in competitive binding assays, while ipamorelin demonstrates >100-fold selectivity for GHSR-1a over GHRH-R systems. Cross-reactivity screening panels confirm minimal off-target interactions for both compounds across extended receptor arrays.
- Kinetic binding analyses using surface plasmon resonance methodology demonstrate differential association/dissociation rate constants. Tesamorelin exhibits rapid association kinetics with GHRH-R (kon ~10^7 M^-1s^-1) and relatively slow dissociation rates (koff ~10^-3 s^-1), resulting in prolonged receptor occupancy. Ipamorelin shows comparable association rates with GHSR-1a but faster dissociation kinetics, suggesting distinct receptor engagement dynamics.
- Signaling Pathway Engagement
- Downstream Effector Systems
- Tesamorelin-mediated GHRH-R activation triggers robust Gαs/adenylyl cyclase signaling cascades in transfected cell systems. Time-course studies demonstrate peak cAMP accumulation within 15-30 minutes of compound addition, with sustained elevation maintained for several hours. Protein kinase A (PKA) activation assays show parallel increases in kinase activity, confirming functional coupling to downstream effector systems.
- Ipamorelin-induced GHSR-1a activation primarily engages Gq/11-mediated phospholipase C (PLC) pathways. Calcium imaging studies in GHSR-1a-expressing cells reveal rapid calcium transients (peak response <60 seconds) followed by sustained elevation phases. IP3 accumulation assays confirm PLC activation, while diacylglycerol measurements demonstrate parallel lipid messenger generation.
- Enzyme Kinetics and Metabolic Stability
- Comparative stability assessments in cell culture media demonstrate enhanced proteolytic resistance for both compounds relative to native peptide hormones. Tesamorelin exhibits extended half-life profiles in serum-containing media (>24 hours), while ipamorelin shows moderate stability (4-8 hours) under identical conditions. Mass spectrometry analysis identifies specific cleavage sites and degradation products under various enzymatic conditions.
- Research Summary
- Tesamorelin and ipamorelin represent pharmacologically distinct research tools for investigating growth hormone regulatory pathways in vitro. Their differential receptor selectivity profiles (GHRH-R versus GHSR-1a), distinct signaling pathway engagement (Gαs/cAMP versus Gq/calcium), and varying stability characteristics provide complementary approaches for mechanistic studies. These compounds offer valuable experimental models for elucidating growth hormone secretagogue pharmacology in controlled cellular systems, with well-characterized binding kinetics and functional responses across multiple assay platforms.
- All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition.
- Hexarelin
- TB-500
- Epithalon
- Ipamorelin
- Tirzepatide
- CJC-1295 DAC
- PT-141
- Semaglutide
- Selank
- BPC-157
- Sermorelin
- Melanotan 2
- IGF LR3
- Tesamorelin
- AICAR
- IGF-DES
- GHRP 2
- Albuterol
- Tamoxifen
- Letrozole
- Clomiphene
- Tadalafil
- Clenbuterol
- Anastrozole
- Finasteride
- Exemestane
- Sildenafil
- Yohimbine
- Bacteriostatic Water Recent Posts Melanotan 2 (MT2): Mechanism, Research, and Safety Considerations Ipamorelin: The Selective GHRP, Explained Tesamorelin: The GHRH Analog Studied for Visceral Fat Sermorelin: The Original GHRH Analog, Explained CJC-1295: How the GHRH Analog Works, and What Research Shows
- Already a customer? Sign In
- Create Account
- All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.
- ElementSarms is a chemical supplier. ElementSarms is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. ElementSarms is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.
- Sarms
- Stacks
- Research Liquids
- Albuterol 5MG/ML | 30ML with dropper
- Anastrozole 1.5MG/ML | 30ML with dropper
- Clomiphene 50MG/ML | 30ML with dropper
- Finasteride 5MG/ML | 30ML with dropper
- Letrozole 3.5 MG/ML | 30ML with dropper
- LiquiCia 30MG/ML | 30ML with dropper
- LiquiCia T50 50MG/ML | 30ML with dropper
- LiquiClen 200MCG/ML | 30ML with dropper
- Liquistane / Exemestane 25MG/ML | 30ML with dropper
- LiquiTamo 20MG/ML | 30ML with dropper
- LiquiVia 25MG/ML | 30 ML with dropper
- T3 LIOTHYRONINE 200MCG/ML | 30ML with dropper
- Toremifene Citrate 60MG/ML | 30ML with dropper
- Yohimbine HCL 10MG/ML | 30ML with dropper
- Research Peptides
- Aicar 50MG
- BPC-157 + TB-500 Blend 2mg ea/ 4MG
- BPC-157 5MG
- CJC-1295 + DAC 2MG
- CJC-1295 | No DAC 2MG
- Epithalon 10MG
- Frag Premium 176-191 5MG
- GHK-CU Copper Peptide 50MG
- GHRP-2 5MG
- GHRP-6 5MG
- Hexarelin 5MG
- IGF-1 DES 1MG
- IGF-1 LR3 1MG
- Ipamorelin 5MG
- Melanotan 2 10MG
- NAD+ 500MG
- PT-141 / Bremelanotide 10MG
- GLP-1/GIP/GCG (RT)
- Selank 5MG
- GLP1 (SM)
- Sermorelin 5MG
- TB-500 5MG
- GIP/GLP-1 (TZ)
- PDE5 Inhibitors
- GLP-1
- Diluents
- Bacteriostatic Water 10ML